Skip to content
AI.info

The Pulse

Faex adds investigational Ebola and H. pylori screening to AI platform

Faex Health has added Ebola and H. pylori to an investigational platform that analyzes smartphone images of stool. Neither indication has entered clinical trials or received FDA clearance or approval.

Faex adds investigational Ebola and H. pylori screening to AI platform

Faex Health has added Ebola virus disease and Helicobacter pylori to an investigational AI platform that analyzes smartphone images of stool. The additions bring the company’s internally validated panel to 18 gastrointestinal and related health conditions, according to its Nov. 20 announcement.

Neither new indication has entered clinical trials or received U.S. Food and Drug Administration clearance or approval. The company says all indications have undergone internal validation, but the findings have not been independently replicated or peer reviewed as a complete panel.

Preliminary signals, not diagnoses

Co-founder and CEO Landon Nattrass presented the additions during a virtual event hosted by HITLAB’s Center for AI Testing and Evidence. The platform examines photographs taken with a standard smartphone camera for characteristics including color, consistency, texture, blood, mucus and other anomalies.

The resulting indicators are preliminary and intended for health awareness and professional review, rather than as medical diagnoses. The platform is designed to support monitoring through repeated images over time. It provides Bristol Stool Form Scale classifications and evaluates seven categories of visual anomalies.

Different uses under investigation

For H. pylori, Faex is exploring whether image analysis can provide a preliminary signal that encourages follow-up testing and medical evaluation. The company describes the bacterium as affecting approximately half of the world’s population and as a major cause of peptic ulcer disease and an established risk factor for gastric cancer.

Many people with the infection have no symptoms. Conventional testing typically requires a urea breath test, stool antigen test or endoscopic biopsy.

For Ebola, the company is investigating whether stool patterns could contribute to preliminary triage in outbreak environments, including where laboratory resources are limited. Ebola virus disease is rare but potentially fatal and can cause severe gastrointestinal symptoms, including diarrhea and significant fluid loss.

Confirmatory diagnosis requires specialized laboratory testing, typically using reverse transcription polymerase chain reaction. The technology is not intended to diagnose Ebola or replace laboratory testing, infection-control procedures or clinical assessment.

Other research and commercial use

The investigational panel spans five clinical categories, from infectious diseases to chronic and inflammatory disorders. The panel also includes indicators associated with colorectal cancer risk, precancerous polyps, Crohn’s disease, ulcerative colitis, irritable bowel syndrome, celiac disease and gastrointestinal bleeding.

A separate ongoing FECAL-AI clinical trial at Hospital Dr. Sótero del Río in Chile concerns colorectal cancer screening. Investigators there are evaluating the platform’s image-derived signals against conventional fecal immunochemical testing.

Faex is also exploring the design of a larger colorectal cancer screening study in the United Kingdom involving the National Health Service and the National Institute for Health and Care Research. The proposed program remains in planning and has not received protocol approval.

The company reports four signed agreements representing approximately 150,000 covered lives, with its first 50,000 covered lives active as of November 2026. It is also conducting exploratory research into stool-visible indicators associated with more than 100 additional health conditions.

Sources

  1. Original source · Press release Faex Health prnewswire.com

Related stories

Explore

More articles